从风湿科医生视角看VEXAS综合征:西班牙全国队列的洞见
这项多中心横断面回顾性研究纳入西班牙126家医院2020年12月至2024年1月诊断的39例男性VEXAS综合征患者,描述其临床谱并分析基因型-表型关联。常见表现为皮损(87.18%)、多关节炎(82.05%)和发热(79.49%),肾脏受累占20.51%。全部检出UBA1突变,M41V与肾脏受累显著相关,M41T与深静脉血栓和血小板减少相关。
要点
- 39例男性VEXAS患者中皮损87.18%、多关节炎82.05%、发热79.49%,肾脏受累20.51%。
- 全部患者检出UBA1突变:18例M41L、14例M41T、6例M41V、1例c.209T>A新变异。
- M41V与肾脏受累显著相关,M41T与深静脉血栓和血小板减少相关。
核心结论
- 本研究揭示风湿科诊疗场景下VEXAS综合征的临床谱,关节症状和肾脏受累的患病率高于既往报告。
- 观察到基因型-表型关联:M41V与肾脏受累显著相关,M41T与深静脉血栓和血小板减少相关。
- 描述了一个位于c.209T>A位点、推测为致病性的VEXAS综合征新变异。
- 这些发现有助于加深对VEXAS综合征的认识,并可能为未来的诊断和治疗策略提供参考。
研究设计与样本
- 多中心、横断面、回顾性研究,覆盖西班牙126家医院。
- 纳入2020年12月至2024年1月间诊断的VEXAS综合征患者。
- 从病历中收集人口学数据、临床表现、实验室检查、遗传分析、治疗和结局。
主要发现
- 共纳入39例男性患者,诊断时平均年龄72.78岁。
- 常见表现为皮损87.18%、多关节炎82.05%、发热79.49%;肾脏受累占20.51%。
- 遗传检测证实全部病例存在UBA1突变:18例M41L、14例M41T、6例M41V和1例位于c.209T>A、意义不明的新变异。
- M41V突变与肾脏受累显著相关,M41T与深静脉血栓和血小板减少相关。
- 全部患者使用糖皮质激素,诊断后缓解率提高(55.26% vs 97.14%),可能受给药剂量增加影响;IL-6抑制剂和JAK抑制剂显示有前景的缓解率(分别为75%和76.92%)。
关键数值与推荐
- 39例男性患者诊断时平均年龄72.78岁。
- 皮损87.18%、多关节炎82.05%、发热79.49%、肾脏受累20.51%。
- UBA1突变分布:M41L 18例、M41T 14例、M41V 6例、c.209T>A新变异1例。
- 糖皮质激素缓解率诊断后55.26% vs 97.14%;IL-6抑制剂缓解率75%,JAK抑制剂缓解率76.92%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the clinical spectrum of VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome in patients managed by rheumatology units and analyse genotype-phenotype correlations. METHODS: A multicentre, cross-sectional, retrospective study was conducted across 126 Spanish hospitals. Patients with VEXAS syndrome diagnosed between December 2020 and January 2024 were included. Demographic data, clinical manifestations, laboratory findings, genetic analyses, treatments and outcomes were collected from medical records. RESULTS: Thirty-nine male patients were included (mean age at diagnosis: 72.78 years). Common manifestations were cutaneous lesions (87.18%), polyarthritis (82.05%) and fever (79.49%). Renal involvement was observed in 20.51% of patients. Genetic testing confirmed ubiquitin-like modifier-activating enzyme 1 mutations in all cases: 18 M41L, 14 M41T, 6 M41V and 1 novel mutation of unknown significance at site c.209T>A. The M41V mutation was significantly associated with renal involvement, while M41T was linked to deep vein thrombosis and thrombocytopaenia. Glucocorticoids were used in all patients, with improved response rates post-diagnosis (55.26% vs 97.14%) probably influenced by an increase in administered doses. IL-6 inhibitors and JAK inhibitors showed promising response rates (75% and 76.92%, respectively). CONCLUSIONS: This study provides insights into the clinical spectrum of VEXAS syndrome in rheumatology settings, highlighting a higher prevalence of joint symptoms and renal involvement than previously reported. Genotype-phenotype correlations were observed, with M41V significantly associated with renal involvement and M41T linked to deep vein thrombosis and thrombocytopaenia. A new, presumably causative variant of VEXAS syndrome at site c.209T>A was described. These findings contribute to the growing understanding of VEXAS syndrome and may inform future diagnostic and treatment strategies.
引用
- García-Escudero P, López-Gómez M, López BM, et al. VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort. Rheumatology (Oxford). 2025. PMID: 39937690. doi:10.1093/rheumatology/keaf094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。